Chief Legal Officer · Foghorn Therapeutics Inc. (FHTX)

Michael LaCascia

FY2020 is the first fiscal year CompBrief holds for Michael LaCascia as a named executive officer of Foghorn Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,988,838

Salary $59,423Stock awards $0Bonus $60,000

2nd of 4 named executive officers at Foghorn Therapeutics by FY2020 total.

4 named officers on file for Foghorn Therapeutics, FY2020

Michael LaCascia’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Foghorn Therapeutics’s whole pay program stands against its peers

  • Foghorn Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on FHTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 1, 2021 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Michael LaCascia’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Michael LaCascia compensation by year

Foghorn Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Foghorn Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$59,423
Bonus$60,000
Stock awards$0
Option awards$1,869,416
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$1,988,838

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Foghorn Therapeutics Inc. DEF 14A filed June 1, 2021, accession 0001193125-21-178596, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Foghorn Therapeutics Inc. filed document, accession 0001193125-21-178596. Every figure is read from that document and cited to the page and table it appears in. Filed June 1, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option162,162—$17.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Foghorn Therapeutics Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

4 Form 4 lines since the FY2020 proxy (filed June 1, 2021)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-01-30Grant or award derivative—295,000$5.71295,000
2025-01-22Grant or award derivative—126,000$4.37126,000
2024-01-24Grant or award derivative—100,000$3.06100,000
2023-01-26Grant or award derivative—90,000$0.0090,000

The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Foghorn Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Adrian GottschalkPresident and Chief Executive Officer$2,624,575
Michael LaCascia · this pageChief Legal Officer$1,988,838
Carl DeciccoFormer Chief Scientific Officer(5)$1,218,464
Samuel AgrestaChief Medical Officer$1,053,797

The full Foghorn Therapeutics compensation record

free company brief

This page is one person within Foghorn Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Foghorn Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael LaCascia's compensation dossier · One-time report. No refunds.